Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Capital Expenditures (2016 - 2026)

Heron Therapeutics filings provide 15 years of Capital Expenditures readings, the most recent being $391000.0 for Q1 2026.

  • On a quarterly basis, Capital Expenditures rose 258.72% to $391000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $599000.0, a 58.05% decrease, with the full-year FY2025 number at $317000.0, down 81.42% from a year prior.
  • Capital Expenditures hit $391000.0 in Q1 2026 for Heron Therapeutics, up from $208000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $1.0 million in Q1 2022 to a low of $45000.0 in Q3 2022.
  • Median Capital Expenditures over the past 5 years was $322000.0 (2022), compared with a mean of $395923.1.
  • Biggest five-year swings in Capital Expenditures: tumbled 97.06% in 2022 and later soared 1662.22% in 2023.
  • Heron Therapeutics' Capital Expenditures stood at $414000.0 in 2022, then plummeted by 39.61% to $250000.0 in 2023, then surged by 155.2% to $638000.0 in 2024, then plummeted by 67.4% to $208000.0 in 2025, then skyrocketed by 87.98% to $391000.0 in 2026.
  • The last three reported values for Capital Expenditures were $391000.0 (Q1 2026), $208000.0 (Q2 2025), and $109000.0 (Q1 2025) per Business Quant data.